BioSpace News Archive

Innate Pharma SA announced preliminary data from the mycosis fungoides cohort of the Phase 2 TELLOMAK clinical trial, evaluating lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, in an oral presentation at the 16th International Conference on Malignant Lymphoma.

Emalex Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced that its Phase 2b clinical trial evaluating the efficacy and safety of ecopipam for the treatment of pediatric patients with Tourette Syndrome has reached 100% percent enrollment.

Valeo Pharma Inc., a Canadian pharmaceutical company, announced that commercialization of Enerzair Breezhaler and Atectura Breezhaler has commenced following product shipments across Canada and the initial deployment of its national respiratory sales force.

Vedere Bio II, Inc., a company developing next-generation ocular gene therapies for vision restoration and preservation in patients with vision loss due to photoreceptor death, announced the appointment of Gabor Veres, Ph.D., as Chief Scientific Officer.

4D pharma plc announces Christophe Carite, Development Director, will deliver a presentation on 4D pharma’s strategy and capabilities for the manufacturing of its Live Biotherapeutic drug candidates at the upcoming virtual Microbiome Movement Drug Development Summit, on Thursday, July 1 at 2.15pm EDT.

Pear Therapeutics, Inc., the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp., a special purpose acquisition company whose management team is associated with the Pritzker Vlock Family Office, announced they have entered into a definitive business combination agreement.

- vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv’s novel antagonist of RAGE (the receptor for advanced glycation endproducts).

BioReference Laboratories, Inc. today announced a COVID-19 testing program for U.S. based crew and guests who cruise with Royal Caribbean Group, helping provide a safe environment for travelers.

Company Invites Individual and Institutional Investors, as well as Analysts and Advisors, to Attend Its Real-Time, Interactive Presentation on Wednesday, June 23, 2021

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), today announced that the U.S. Food and Drug Administration (“FDA”) has authorized its investigational new drug (“IND”) application for the study of CLBS201, a CD34+ cell therapy for the treatment of diabetic kidney disease (“DKD”).